Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 14 May 2004 |
| Genmab, current statement of shareholdings | 12 May 2004 |
| Genmab, Capital Increase in Genmab as a Result of Employees' Warrant Exercise | 11 May 2004 |
| Genmab, articles of association dated May 11, 2004 | 11 May 2004 |
| Genmab, current statement of shareholdings | 6 May 2004 |